Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies
Conditions
Interventions
BR101801 (Phase Ia)
BR101801 (Phase Ib)
Locations
9
United States
Henry Ford Hospital
Detroit, Michigan, United States
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
Inje University Busan Paik Hospital
Busan, South Korea
Asan Medical Center
Seoul, South Korea
Start Date
April 21, 2020
Primary Completion Date
September 21, 2023
Completion Date
September 21, 2023
Last Updated
September 10, 2025
NCT06846671
NCT07545603
NCT07218341
NCT06548152
NCT06149286
NCT07260812
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions